| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8743827 | Transplant Immunology | 2017 | 6 Pages |
Abstract
Ibrutinib is effective in suppressing alloantibody responses through blocking BTK-mediated BCR signaling, leading to reduction of B cells and short-lived plasma cells in the spleens. Use of ibrutinib may provide benefits to HLA-sensitized transplant patients for alloantibody suppression.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Irene Kim, Gordon Wu, Ning-ning Chai, Andrew S. Klein, Stanley Jordan,